BridgeMD
Using a fixed dosage of follitropin delta for ovarian stimulation for intrauterine insemination.
EU CTIS ID: 2025-520681-22-00
What this study is testing
To observe the effect of a fixed dose of follitropin delta (3.66mcg) on the ovarian response during ovarian stimulation for IUI.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Normo-ovulatory patients
- 18 – 38 included years old
- BMI between 18 and 29 included kg/m²
- Regular menstrual cycles
- At least one healthy Fallopian tube
- Normal uterus cavity
You likely can't join if
- Endometriosis Stage III
- Tumors (including meningioma) whose development is known or suspected to be progesterone-dependent
- History of hepatic dysfunction
- Severe spermatogenesis disorders
- Have been receiving progestogen therapy for more than 6 months
- Known contraindication to hormonal treatments (progestogens or oestrogens), or with a history of adverse events related to their use.
See the full eligibility criteria
- Normo-ovulatory patients
- 18 – 38 included years old
- BMI between 18 and 29 included kg/m²
- Regular menstrual cycles
- At least one healthy Fallopian tube
- Normal uterus cavity
- First treatment for IUI
- Affiliation to the social security
- Endometriosis Stage III
- Tumors (including meningioma) whose development is known or suspected to be progesterone-dependent
- History of hepatic dysfunction
- Severe spermatogenesis disorders
- Have been receiving progestogen therapy for more than 6 months
- Known contraindication to hormonal treatments (progestogens or oestrogens), or with a history of adverse events related to their use.
- Previous thromboembolism events during or following the use of gonadotrophins or with high risk factors for thromboembolic events (venous or arterial)
- Hypersensitivity to the active substance or to any of the excipients
- High risk of OHSS such as women with AMH ≥ 35 pmol/L
- History of severe uterine malformation (unicornuate or bicornuate uterus)
- Past history of ovarian torsion
- Gynecological bleeding of unknown etiology
- Uncontrolled thyroid dysfunction
- Uncontrolled adrenal dysfunction
- Hydrosalpynx
- Women with Poly Cystic Ovary Syndrom
- Breast pathologies not compatible with gonadotrophin stimulation
- Use of infertility medications that could affect follicle stimulation and maturation such as GH
- History of OHSS or excessive response to gonadotrophins
- Chronic disease with contraindication to ovarian stimulation with gonadotrophins
- Known genetic disease
- Hypothalamus or pituitary tumors
- Ovarian, uterine or breast carcinoma
- Ovarian hypertrophy or ovarian cyst not due to polycystic ovary syndrome
- Not able to understand and sign the written informed consent form
- Previous or current treatment with gonadotrophins
- Primary ovarian failure
- Genital malformations incompatible with pregnancy
- Uterine fibroids incompatible with pregnancy
- Protected persons (pregnant women, nursing mothers, person under guardianship, minors, persons deprived of liberty, and persons unable to give consent)
- Participation in other interventional research
- Total mobile sperm count <1 million
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.